CRPHAGE

Welcome to the Brand page for “CRPHAGE”, which is offered here for Pharmaceutical preparations for targeting and destroying bacteria; pharmaceutical preparations for the treatment of antibiotic-resistant bacterial infections and microbiome-related disorders; pharmaceutical preparations for use in the field of engineered bacteriophage; pharmaceuticals designed to deliver highly targeted therapeutic modulation for patients suffering from a variety of diseases, including cancer, autoimmune and inflammatory diseases including transplantation and delayed-type hypersensitivity, respiratory diseases, gastrointestinal diseases, cardiovascular and metabolic diseases, pathogen infections, musculoskeletal diseases, ophthalmologic and dermatologic diseases, genitourinary diseases, degenerative diseases, and orphan diseases;.

Its status is currently believed to be active. Its class is unavailable. “CRPHAGE” is believed to be currently owned by “Locus Biosciences, Inc.”